Levodopa inhalation - Acorda Therapeutics

Drug Profile

Levodopa inhalation - Acorda Therapeutics

Alternative Names: CVT-301; INBRIJA

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Civitas Therapeutics
  • Developer Acorda Therapeutics
  • Class Antiparkinsonians; Catecholamines; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Parkinson's disease
  • Phase I Asthma; Smoking withdrawal

Most Recent Events

  • 29 May 2018 Acorda Therapeutics expects an opinion from Committee for Medicinal Products for Human Use related to MAA for levodopa inhalation for Parkinson's disease (Adjunctive treatment) within December 2018 (210 days)
  • 29 May 2018 EMA validates MAA for levodopa inhalation for Parkinson's disease (Adjunctive treatment)
  • 01 May 2018 Civitas Therapeutics completes a phase III extension study for Parkinson's disease in USA, Poland, Czech Republic, Spain and Canada (Inhalation) (NCT02242487)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top